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indicated presence of muscarinic acetylcholine receptors 
with a radioligand affinity comparable to that reported in 
mice. In conclusion, muscarinic acetylcholine receptor sub-
types are present in the naked mole-rat and contribute to 
antinociception in the naked mole-rat.
Keywords Naked mole-rat · Cholinergic receptors · 
Muscarinic, antinociception, formalin test
Introduction
Chronic pain is a major challenge in pain research and medi-
cine, since it is often multifactorial and very difficult to treat 
(Pergolizzi et al. 2012). Novel treatment strategies against 
chronic pain are desirable, and in the search for such treat-
ments, the use of experimental animal models is necessary.
The involvement of the muscarinic cholinergic receptor 
system in antinociception is well established. Five muscarinic 
receptor subtypes have been identified so far, denominated 
M1–M5 (based on pharmacological characterization) or m1–
m5 (based on genes coding for the receptors) (Caulfield and 
Birdsall 1998). Antinociceptive effects of cholinomimetic 
drugs, such as oxotremorine (George et al. 1962; Harris et al. 
1969; Ireson 1970; Bartolini et al. 1987), pilocarpine (Hend-
ershot and Forsaith 1959), physostigmine (Harris et al. 1969; 
Ireson 1970), tremorine, arecoline and diisopropylphos-
phorofluoridate (DEP) have been investigated in different 
laboratory animal species (Bartolini et al. 2011). Muscarinic 
receptor subtypes interact with other receptor systems in the 
spinal cord including the GABAergic, opioid, serotonergic 
and adrenergic systems (Baba et al. 1998; Li and Zhuo 2001; 
Chen and Pan 2003; Honda et al. 2003; Abelson and Höglund 
2004; Chen and Pan 2004; Kommalage and Höglund 2005b; 
Kommalage and Höglund 2005a). In addition, cholinergic 
Abstract The present study investigated the choliner-
gic system in the African naked mole-rat (Heterocephalus 
glaber) with focus on the muscarinic acetylcholine receptor 
subtypes M1 and M4. The protein sequences for the subtypes 
m1–5 of the naked mole-rat were compared to that of the 
house mouse (Mus musculus) using basic local alignment 
search tool (BLAST). The presence and function of M1 and 
M4 was investigated in vivo, using the formalin test with the 
muscarinic receptor agonists xanomeline and VU0152100. 
Spinal cord tissue from the naked mole-rat was used for 
receptor saturation binding studies with [3H]-N-methylsco-
polamine. The BLAST test revealed 95 % protein sequence 
homology showing the naked mole-rat to have the genetic 
potential to express all five muscarinic acetylcholine recep-
tor subtypes. A significant reduction in pain behavior was 
demonstrated after administration of 8.4 mg/kg in the for-
malin test. Administration of 50 mg/kg VU0152100 resulted 
in a non-significant tendency towards antinociception. The 
antinociceptive effects were reversed by the muscarinic 
acetylcholine receptor antagonist atropine. Binding studies 
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antagonists have been shown to block antinociception in rats 
(Abelson and Höglund 2002).
The muscarinic receptor subtype M1 is involved in neu-
ronal activity and analgesia (Bartolini et al. 2011; Martino 
et al. 2011), and is highly expressed in the brain, but not the 
spinal cord of rats (Höglund and Baghdoyan 1997; Barto-
lini et al. 2011), while presence in human spinal cord has 
been suggested (Villiger and Faull 1985).
The M4 receptor subtype is highly concentrated in the 
superficial layers of the spinal cord dorsal horn, in the brain 
of both rats and humans (Schechtmann et al. 2008), and in 
high levels in the striatum (Levey et al. 1991; Levey 1993). 
The M4 receptors are considered important in muscarinic-
mediated analgesia together with the M2 subtype (Ellis 
et al. 1999; Zhang et al. 2002; Chen and Pan 2004; Mar-
tino et al. 2011). The suggested antinociception-mediating 
effects and for the muscarinic receptor subtypes M1 and 
M4 makes them interesting potential drug targets for pain 
relief, but there is still a considerable lack of knowledge 
about the specific mechanism by which the muscarinic 
receptors exert their antinociceptive effect. By undertaking 
comparative studies of the muscarinic cholinergic receptor 
system in different species, we strive to gather important 
information about the antinociceptive functions of this sys-
tem that would contribute to an increased understanding of 
cholinergic antinociceptive mechanisms.
The African naked mole-rat (Heterocephalus glaber) 
possesses several unusual features compared to other 
rodents, including a pain system with several deviations 
from the pain system of other mammals (Kanui et al. 1993; 
Towett and Kanui 1993; Towett et al. 2006, 2009; Park et al. 
2008; Kim et al. 2011). It has recently been established as a 
model for studying cholinergic involvement in pain behav-
ior (Dulu et al. 2014). Thus, it is possible to investigate 
whether the difference in pain behavior in the naked mole-
rat is related to differences in the presence and function of 
muscarinic receptors, compared to other species.
The aim of the present study was to confirm the presence 
and function of muscarinic receptors, in particular the M1 
and M4 subtypes, in the naked mole-rat, using the forma-
lin test and saturation binding studies on spinal cord tissue. 
It was hypothesized that the muscarinic receptor subtypes 
M1 and M4 contribute to the regulation of pain transmission 
in the naked mole-rat, similar to commons rodent species 
used in biomedical pain research.
Materials and methods
Animals
African naked mole-rats were captured under a per-
mit issued by the Kenya Wildlife Services (KWS). The 
experimental procedures were performed after ethical 
approval of KWS and of the Institutional Animal Care 
and Use Committee (the Faculty of Veterinary Medicine 
Research Ethics Committee of the University of Nairobi). 
The experimental procedures were conducted in accord-
ance with the guidelines set forth by the American Physi-
ological Society (American Physiological Society 2002).
The mole-rats were captured from Kathekani, Makueni 
County in Southeastern Kenya, during the months of July–
August. A total of 100 animals of both sexes were captured, 
varying in mass (12.9–54.7 g) and age. Nineteen animals 
died of unknown causes from the time of capture until 
the experiment was initiated. The animals were allowed a 
1-month acclimatization period in the laboratory.
For the receptor binding studies, ten naked mole-rats 
were euthanized by cervical dislocation and the spinal 
cords were removed. None of these animals had undergone 
any pharmacological treatments.
Housing
The animals were housed in one housing unit consisting 
of four plastic barrels; two measured 46 cm in diameter 
and 30 cm tall and two measured 39 cm in diameter and 
36 cm tall. The barrels were connected with plastic tubing 
to mimic the burrows. The ambient temperature was kept 
at 25 ± 2 °C and the relative humidity at 45–50 %. The 
bedding consisted of coarse sawdust and was changed as 
needed. The animals were fed on fresh carrots and sweet 
potatoes ad libitum and no water was supplied.
Basic local alignment search tool (BLAST) analysis
The accession numbers for the amino acid sequences 
encoded by m1–m5 in the house mouse (Mus musculus) and 
in the naked mole-rat were found via the National Center 
for Biotechnology Information. A BLAST comparison was 
made on the basis of each of the accession numbers and 
the maximal identity, query cover, maximal score and total 
score to a similar sequence in the naked mole-rat genome 
was noted.
Formalin test
The in vivo formalin tests on the African naked mole-rats 
were performed at South Eastern Kenya University, Kitui, 
Kenya. Thirty-seven animals were injected subcutaneously 
(s.c.) with 20 μL of 3.7 % (w/v) formalin or 0.9 % (w/v) 
NaCl (saline vehicle) dorsally in the right hind paw using 
a 27G needle and a 1 ml syringe, based on a previous 
study (Towett et al. 2009), and placed in a glass observa-
tion chamber measuring 15 × 14.5 × 14.5 cm. Animals 
were observed immediately after injection and the time 
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spent licking, biting or flinching the injected paw were 
recorded in blocks of 5 min during a total of 60 min. The 
observer was blinded to the formalin or vehicle treatments. 
During experiments with muscarinic receptor ligands, the 
animals were injected with 20 μL formalin s.c. dorsally in 
the right hind paw 30 min after the intraperitoneal (i.p.) 
injection of ligand. Immediately after formalin injection, 
the animal was placed in the observation chamber for an 
hour and observed as described above. After each test the 
animal’s motor skills and proprioception were checked. 
This was done by placing the animal on its back to see if 
it could turn over and also by placing the dorsal surface 
of each hind paw on the table to see if it could sense this 
and turn it over. The majority of the experiments were per-
formed between 8 a.m. and 5 p.m. at a room temperature 
of 25.7–27.8 °C.
Receptor saturation binding
Tissue
Whole spinal cords from ten euthanized naked mole-rats 
were immediately removed and stored in a plastic con-
tainer, submerged in 0.9 % ice-cold NaCl. The tissue was 
stored at −20 °C. Upon arrival at the University of Copen-
hagen, tissues were stored at −80 °C. On the day of the 
experiment, the containers were slowly thawed by plac-
ing the container in cold water. The spinal cords were dis-
sected from the vertebrae in a petri dish kept on ice. The 
dissection was done by exposing the vertebrae and cut-
ting through the vertebrae with scissors. The spinal cord 
was lifted out from the vertebrae with forceps, and dorsal 
roots were cut and discarded to avoid possible contamina-
tion from dorsal root ganglia. Spinal cords were pooled 
in tubes and weighed so each contained a minimum of 
200 mg. Since the tissue available was limited, it was not 
possible to isolate the lumbar region alone, although this 
region could be assumed to correspond to the behavioral 
tests conducted. The tubes were kept frozen at −80 °C 
until used for binding experiments.
Spinal cord tissue (200–300 mg) was thawed and 
homogenized at 24,000 rpm for 1 min in 50 volumes of 
ice-cold 30 mM Na+/HEPES wash buffer (pH 7.5 at 4 °C) 
using an Ultra-Turrax (IKA, Staufen, Germany) homog-
enizer and then centrifuged at 48,000×g for 20 min at 
4 °C. The resulting pellet was resuspended in 50 volumes 
of ice-cold wash buffer and re-centrifuged. The washed 
pellet was finally resuspended in 50 volumes of 30 mM 
Na +/HEPES assay buffer (pH 7.5 at room temperature). 
Protein concentration of the membrane suspension was 
determined using the micro-BCA protein assay (Thermo 
Fisher Scientific, Rockford, IL, USA).
Saturation binding
Saturation binding of [3H]-N-methylscopolamine ([3H-
NMS)] (85.5 Ci/mmol; PerkinElmer, Waltham, MA, 
USA) to spinal cord membranes was carried out in trip-
licate in glass tubes for 1 h at room temperature in a 
volume of 0.25 ml using 0.01–4.0 nM radiolabel. Non-
specific binding at each radiolabel concentration was 
determined using 1 µM atropine. The binding reaction 
was terminated by adding 3 ml of ice-cold wash buffer 
and rapid vacuum filtration through GF/B glass fiber fil-
ters (VWR International, Denmark) pre-soaked for 1 h in 
0.3 % (w/v) polyethylenimine/50 mM Tris base. Filters 
were immediately rinsed once with 3 ml ice-cold wash 
buffer. Tissue-bound radioactivity was extracted from the 
filters by overnight immersion in 3 ml EcoScint A scin-
tillation fluid (National Diagnostics, Atlanta, GA, USA) 
and radioactivity was measured as DPM by liquid scintil-
lation counting.
Drugs and chemicals
Xanomeline was chosen because of its properties as mus-
carinic receptor agonist selective for M1 and M4 (Martino 
et al. 2011). VU152100 was chosen because of its proper-
ties as positive allosteric modulator of muscarinic receptor 
M4 (Brady et al. 2008).
Xanomeline l-tartrate hydrate, VU0152100, and atro-
pine sulfate were obtained from Sigma–Aldrich, Denmark. 
Xanomeline and atropine were dissolved in 0.9 % (w/v) 
saline and stored at 2–4 °C. VU0152100 was dissolved in 
20 % (v/v) DMSO and stored at 2–4 °C.
Data analysis
Formalin test
The data were analyzed using two-way ANOVA with 
Bonferroni’s post hoc test in GraphPad Prism ver-
sion 5.0. Data are presented as mean time (±SEM) in 
graphs. P < 0.05 was considered statistically significantly 
different.
Saturation binding
Receptor saturation binding data were analyzed in Graph-
Pad Prism version 5.0 using non-linear regression, satura-
tion binding, one site, total + non-specific binding, robust 
fit to determine the Kd and Bmax values and using non-linear 
regression, one site specific binding to determine the Hill 
coefficient, nH.
10 J Comp Physiol A (2016) 202:7–15
1 3
Results
Blast
Using GenBank data from the National Center for Bio-
technology Information (NCBI), the accession num-
bers and amino acid sequences encoded by m1–m5 in the 
house mouse (Mus musculus) and in the naked mole-rat 
were obtained. Table 1 shows the results from comparing 
the amino acid sequences of mAChRs in the house mouse 
with the sequences of mAChRs in the naked mole-rat via 
BLAST.
Formalin test
Control study
There was a significant difference in pain behavior between 
injection of 20 μL 10 % formalin and saline s.c. in the time 
intervals 0–5 min (P < 0.01), 40–45 min (P < 0.05), and 
45–60 min (P < 0.001) (Fig. 1). No deterioration in propri-
oception or motor skills was observed. On the basis of the 
biphasic appearance of the graph (Fig. 1) and the signifi-
cant differences between the formalin and saline injections, 
the early and late phase were determined to be 0–10 and 
35–60 min, respectively. Although there were no signifi-
cant differences during the 5–10 and 35–40 min intervals, 
they were included due to observed pain behavior during 
the 5–10 min interval and the slight incline beginning from 
35 min. All results for the experiments of control groups, 
xanomeline and VU0152100 were found to follow a Gauss-
ian distribution, as determined with D’Agostino and Pear-
son omnibus normality test.
Xanomeline
The effect of intraperitoneal (i.p.) injection of xanomeline 
in doses of 0.84, 2.8, 8.4 and 28.1 mg/kg was investigated 
Table 1  An overview of the results from comparing gene sequences of mAChRs in the house mouse with protein sequences of mAChRs in the 
African naked mole-rat
The first column shows accession numbers for the protein sequences used to compare
Maximal score Total score Query cover (%) Maximal identity (%)
m1 Mus musculus NP_001106167/m1 Heterocephalus glaber EHB02109 652 652 81 95
m2 Mus musculus NP_987076/m2 Heterocephalus glaber EHA98116 891 891 97 97
m3 Mus musculus NP_150372/m3 Heterocephalus glaber EHB16914 1101 1101 100 92
m4 Mus musculus NP_031725/m4 Heterocephalus glaber EHB00279 903 903 100 95
m5 Mus musculus NP_991352/m5 Heterocephalus glaber EHA97883 959 959 100 89
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Fig. 1  a The effect of subcutaneous injection of 20 μl 10 % forma-
lin (filled square) or saline (filled circle) dorsally in the right hind 
paw on pain behavior. A significant difference was found in the time 
intervals 0–5 min (P < 0.01), 40–45 min (P < 0.05), and 45–60 min 
(P < 0.001). Data are shown as mean (±SEM). Number of animals 
(n) = 8 for saline, n = 8 for formalin. Data were analyzed by two-
way ANOVA with Bonferroni’s post hoc test demonstrated using 
GraphPad Prism 5.0. *P < 0.01, **P < 0.05, *P < 0.001. b A com-
parison of the injection of i.p. saline (filled circle) and i.p. atropine 
(unfilled rectangle; 2.5 mg/kg). No significant difference (P > 0.05) 
was found in the late or early phase. Data are shown as mean time 
(±SEM). Number of animals (n) = 8 for saline and n = 5 for atro-
pine. Data were analyzed by two-way ANOVA and Bonferroni’s post 
hoc test using GraphPad Prism 5.0
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and was compared to a control group receiving i.p. injection 
of saline. Doses were based on the study by Martino et al. 
(2011). Xanomeline 28.1 mg/kg was found to affect motor 
functions in the animals. Two out of four animals had no 
proprioception and could not turn over when placed on their 
backs. The third animal had reduced proprioception and could 
turn over from its back while the fourth had normal proprio-
ception and motor skills. Since this makes it impossible to 
distinguish an antinociceptive effect from immobilization, the 
highest dose of xanomeline was omitted from the study.
Results from the control saline group were compared to 
all xanomeline doses and the different xanomeline doses 
were compared to each other, in the 5 min time intervals 
during the early (0–10 min) and late (35–60 min) phases. 
Figure 2a illustrates the relationship between all the 
xanomeline doses and the control group. The xanomeline 
doses of 0.84 and 2.8 mg/kg had no significant effect com-
pared to the control group. I.p. injection of xanomeline 
8.4 mg/kg produced a significant decrease in pain behav-
ior compared to the control group in the late phase, at 
45–50 min (P < 0.001). When comparing this concentra-
tion to the other xanomeline doses, a significant difference 
to 0.84 mg/kg was found during the late phase in the time 
intervals 40–45 min (P < 0.05) and 45–50 min (P < 0.001). 
No deterioration in proprioception or motor skills was 
observed after administration of 0.84–8.4 mg/kg. i.p. injec-
tion of atropine 2.5 mg/kg alone was compared to that of 
the control i.p. saline injection (Fig. 1b). The atropine dose 
was based on the study by Dulu et al. (2014). No significant 
difference was found (P > 0.05). No deterioration in propri-
oception or motor skills was observed. Pain behavior after 
co-administration of 8.4 mg/kg xanomeline with 2.5 mg/kg 
atropine is shown in Fig. 2b. A significant difference was 
found in the late phase at 45–59 min when comparing the 
effect of atropine and xanomeline 8.4 mg/kg with xanome-
line 8.4 mg/kg alone. No deterioration in proprioception or 
motor skills was observed.
Vu0152100
Since VU0152100 was dissolved in 20 % (v/v) DMSO, 
a control group of DMSO was compared to the i.p. 
saline control group. No significant difference was found 
(P > 0.05), and thus the DMSO group was used as a con-
trol group for the VU0152100 experiments. The effect of 
i.p. injection of VU0152100 in a concentration of 50 mg/kg 
was investigated and the mean time (±SEM) spent showing 
pain behavior is shown in Fig. 3. The dose of VU152100 
was based on the study by Brady et al. (2008). No signifi-
cant reduction in pain behavior (P > 0.05) was found when 
compared with the DMSO control group, although a ten-
dency was observed. No deterioration in proprioception or 
motor skills was observed.
The mean time (±SEM) spent showing pain behavior 
after i.p. co-administration of 50 mg/kg VU0152100 with 
2.5 mg/kg atropine is shown in Fig. 3. A significant differ-
ence was found in the late phase (P < 0.05) when compared 
to the i.p. injection of just 50 mg/kg VU0152100. No dete-
rioration in proprioception or motor skills was observed.
Receptor saturation binding assay
With the amount of African naked mole-rat spinal cord tis-
sue available, three receptor saturation binding assays using 
[3H]-NMS were performed. The pooled data are shown 
in Fig. 4. The mean (±SEM) Kd, Bmax and nH values for 
[3H]-NMS binding to mAChRs in naked mole-rat spinal 
cord were: 309 ± 55 pM, 186 ± 7 fmol/mg protein and 
1.08 ± 0.05, respectively.
Discussion
Opioids and non-steroidal anti-inflammatory drugs 
(NSAIDs) are essential when it comes to treating moderate 
to severe pain (Angst and Clark 2006), but adverse effects 
are seen with both (Kaminaga et al. 1999; Pergolizzi et al. 
2012). In addition, opioids are suggested to cause opioid-
induced hyperalgesia (OIH), tolerance development to 
the drug, and potential opioid addiction (Angst and Clark 
2006; Chu et al. 2006; Pergolizzi et al. 2012). Hence, there 
is a need for developing analgesic drugs that affect other 
receptor systems that the opioid.
Neurons with cholinergic receptors in the spinal cord 
terminate both at primary afferent fibers (PAF) and on 
intrinsic neurons like projection neurons, where they have 
the potential to modulate nociceptive information from 
both these types of neurons (George et al. 1962; Harris 
et al. 1969; Ireson 1970; Bartolini et al. 1987, 2011; Caul-
field and Birdsall 1998). The suggested antinociception-
mediating effects for the muscarinic receptor subtypes M1 
and M4 makes them interesting potential drug targets for 
pain relief, but there is still a considerable lack of knowl-
edge about the specific mechanism by which the mus-
carinic receptors exert their antinociceptive effect.
By studying different mammalian species with known 
differences in nociceptive behavior, further knowledge of 
the fundamental mechanisms involved in muscarinic reg-
ulation of antinociception can be obtained. In the present 
investigation, we have studied muscarinic receptors in the 
African naked mole-rat, with regards to the antinociceptive 
effects of muscarinic receptor ligands in vivo, as well as the 
pharmacological properties of their muscarinic receptors 
in vitro.
As mentioned, the naked mole-rat has some unusual 
properties regarding its pain physiology. It has been shown 
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that naked mole-rats develop hyperalgesia when adminis-
tered opioid agonists and then subjected to the hot-plate test 
(Towett et al. 2006). This response is similar to what is seen 
in chronic pain patients treated with opioids who develop 
opioid-induced hyperalgesia (Angst and Clark 2006; Chu 
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Fig. 2  a The effect of i.p. injection of xanomeline in concentra-
tions of 0.84 (unfilled circle), 2.8 (unfilled up pointed triangle) and 
8.4 (filled down pointed triangle) mg/kg compared to a control 
group (filled circle) of i.p. saline injection. A significant difference 
was found in the late phase during the time interval of 45–50 min 
(P < 0.001) when comparing the injection of xanomeline in the con-
centration of 8, 4 mg/kg to the control group, indicated with aaa. A 
significant difference was also found when comparing the injection of 
xanomeline at the concentration of 0.84 mg/kg to xanomeline in the 
concentration of 8, 4 mg/kg during the time intervals of 40–45 min 
(P < 0.05) and 45–50 min (P < 0.001), indicated with b and bbb, 
respectively. Data are shown as mean time (±SEM). Number of ani-
mals (n) = 8 for control, n = 6 for xanomeline 0.84 mg/kg, n = 6 for 
xanomeline 2.8 mg/kg, n = 6 for xanomeline 8.4 mg/kg. Data were 
plotted using GraphPad Prism 5.0. b The effect of i.p. injection of 
xanomeline 8.4 (unfilled circle) mg/kg co-administered with atropine 
(2.5 mg/kg), compared to the i.p. injection of 8.4 (filled down pointed 
triangle) mg/kg xanomeline alone and the saline (filled circle) con-
trol group. Significant differences were found in the late phase during 
the time intervals 35–40 min (P < 0.05) and 45–50 min (P < 0.0001) 
when comparing the injection of xanomeline 8.4 mg/kg alone with 
the control group, indicated with a and aaa, respectively. A sig-
nificant difference was also found in the time interval 45–50 min 
when comparing the injection of xanomeline 8.4 mg/kg alone with 
xanomeline 8.4 mg/kg co-administered with atropine (P < 0.05), indi-
cated with b. No significant difference was found between the con-
trol group and xanomeline 8.4 mg/kg co-administered with atropine. 
Data are shown as mean time (±SEM). Number if animals (n) = 8 
for saline, n = 6 for xanomeline 8.4 mg/kg and n = 5 for xanomeline 
8.4 mg/kg + atropine. Data were analyzed by two-way ANOVA and 
Bonferroni’s post hoc test using GraphPad Prism 5.0
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Fig. 3  The effect of i.p. injections of the control group of 20 % 
DMSO (unfilled circle), 50 mg/kg V0152100 (filled square) and 
co-administration of 50 mg/kg VU0152100 with 2.5 mg/kg atro-
pine (filled up pointed triangle). No significant reduction in pain 
behavior (P > 0.05) was found when comparing IP injection of 
VU0152100 with the i.p. injection of DMSO 20 % control group, or 
with VU0152100 and co-administration of VU0152100 with atro-
pine. A significant difference was found between i.p. injections of 
VU0152100 and co-administration of VU0152100 with atropine, 
in the late phase during the time intervals of 40–50 min (P < 0.05). 
Data are shown as mean time (±SEM). Number of animals (n) = 6 
for DMSO 20 %, n = 6 for VU0152100 and n = 4 for co-adminis-
tration of VU0152100 with atropine. Data were analyzed by two-way 
ANOVA and Bonferroni’s post hoc test using GraphPad Prism 5.0. 
*P < 0.05
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Fig. 4  Receptor saturation binding studies with [3H]-NMS as the 
radioligand performed on African naked mole-rat spinal cord tissue. 
Non-specific binding (unfilled up pointed triangle), total binding 
(unfilled circle) and specific binding (filled circle) are shown. Data 
points are mean (±SEM) of three pooled saturation binding studies 
each conducted in triplicate and are corrected for protein content
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et al. 2006). In addition, the animal has a complete lack of 
cutaneous C-fibers immunoreactive to substance P and cal-
citonin gene-related peptide (Park et al. 2003, 2008).
To the best of our knowledge, the mAChRs have not 
been investigated in the African naked mole-rat, except for 
one prior study (Dulu et al. 2014). Thus, the focus of this 
study was to further investigate the presence and function 
of mAChRs in the naked mole-rat, with the main focus on 
the mAChR subtypes M1 and M4.
Using BLAST it was found that the m1 and m4 recep-
tors of the house mouse (Mus musculus), both were found 
to have a maximal identity of 95 % with m1 and m4 of the 
naked mole-rat. In both cases the total score was the same 
as the maximal score (652 for m1 and 903 for m4), and 
the query cover was found to be 81 and 100 % for the m1 
and m4 sequences, respectively. This shows that the naked 
mole-rat has genes coding for proteins with high similarity 
to mAChRs in the house mouse.
As shown in earlier studies (Kanui et al. 1993; Park et al. 
2008; Towett et al. 2009; Dulu et al. 2014), the formalin test 
is a reliable nociceptive test in the naked mole-rat, which 
was confirmed in this study. The administration of 8.4 mg/
kg (s.c.) xanomeline resulted in a significant decrease 
of pain behavior during the late phase. In the experiment 
with 8.4 mg/kg xanomeline co-administered with 2.5 mg/
kg atropine, a significant difference was found in the late 
phase when compared to the administration of 8.4 mg/
kg xanomeline alone. The effects of xanomeline are sug-
gested to be mediated through binding to the mAChRs M1 
and/or M4 (Martino et al. 2011), which indicates that these 
subtypes should be of importance for the effects observed. 
However, since the actual concentration of xanomeline 
at the site of receptors in the present study is unknown, 
it cannot be ruled out that xanomeline exerts some of its 
actions through other mAChR subtypes than M1 and M4. 
For instance, xanomeline has also been described as an M5 
receptor antagonist (Grant and El-Fakahany 2005), which 
could contribute to the observed effects.
When administering 28.1 mg/kg of xanomeline, it 
was found that the activity of the animals was markedly 
decreased about 20 min after administration and, as men-
tioned above, most of the animals given the 28.1 mg/kg 
dose had reduced proprioception and motor skills after the 
formalin test had been conducted. This could be related to 
several factors. However, the reduced proprioception and 
motor skills were reversed in animals treated with 28.1 mg/
kg xanomeline in co-administration with 2.5 mg/kg atro-
pine. This suggests that mAChRs, at least partly, mediate 
the cause of the reduced motor functions.
In this study, administration of 50 mg/kg of the M4 spe-
cific allosteric agonist VU0152100 did not produce a sig-
nificant decrease in pain behavior, although a tendency was 
observed from 35 min and lasting throughout (Fig. 3). In 
addition, a significant difference was found between co-
administration of VU0152100 with 2.5 mg/kg atropine and 
VU0152100 alone during the late phase. This hints towards 
a possible antinociceptive action of VU0152100 mediated 
through mAChRs, possibly M4.
In none of the experiments with xanomeline and 
VU0152100, a significant decrease in pain behavior dur-
ing the early phase was observed, contrary to what was 
observed in a previous study using the nonspecific mAChR 
agonist oxotremorine in the formalin test (Dulu et al. 2014). 
In that study the drugs were administered i.p. 30 min prior 
to the formalin test, similar to this study with xanomeline 
and VU0152100. Therefore, neither animal species nor 
administration route and time of administration are likely 
the cause of the lack of early phase response the present 
study. A possible explanation for the differences observed 
in antinociception could be different pharmacokinetic pro-
files of these drugs in the naked mole-rat. Other possible 
explanations to the absent effect in the early phase could 
be different stress level in the animals, or variation between 
stocks of animals used in the two studies.
Since an antinociceptive effect of xanomeline similar to 
that of the naked mole-rat was also reported in mice and 
rats (Sheardon et al. 1997; Martino et al. 2011), and since 
the mole-rat has genetic and pharmacological similarities 
regarding mAChRs, it is assumable that the mechanisms of 
action for the antinociceptive effect of mAChRs are simi-
lar in the naked mole-rat and the laboratory mouse. Hence, 
it seems that the behavioral and physiological differences 
in the mole-rats pain system that have been previously 
observed are not related to the mAChR-system.
The saturation binding assay data demonstrates that 
mAChRs are present and have pharmacological function 
in the naked mole-rat. The precise location of the recep-
tors in the spinal cord is, however, not known. This means 
that we cannot conclude if the effects of xanomeline and 
VU0152100 occur by action on excitatory or inhibitory 
interneurons in the spinal cord, on projection neurons, or 
on primary afferent neurons. This could be elucidated by 
studying immunohistochemistry of spinal cord tissue from 
the naked mole-rat. However, since we conclude that the 
muscarinic receptor system of the naked mole-rat des not 
account for the differences in pain behavior compared to 
other rodents, we choose not to proceed with this matter in 
the present study. For the same reason, we choose not to 
investigate the precise composition of mAChR subtypes by 
the use of specific receptor subtypes such as pirenzepine 
(M1 antagonist), AF-DX 116 (M2 receptor antagonist), 
4-DAMP (M3 receptor antagonist) and tropicamide (M4 
receptor antagonist). Hence, this was beyond the scope of 
the present study. However, it would certainly be of great 
interest to investigate this in future studies, to fully charac-
terize the muscarinic receptor system in the naked mole-rat.
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It must also be pointed out since xanomeline and 
VU0152100 were administered systemically, the antino-
ciceptive actions of the drugs are necessarily not solely 
located solely in the spinal cord. Furthermore, it must 
also be pointed out that the number of publications where 
xanomeline or VU152100 have been studied are scarce, 
why the site of action of these substances should be consid-
ered unclear for any species at this stage.
In conclusion, BLAST analysis showed that the Afri-
can naked mole-rat has genes coding for proteins similar 
to all five mAChR subtypes. The results from the formalin 
test suggest the antinociceptive effects of xanomeline and 
VU0152100 to be mediated through mAChRs. A signifi-
cant reduction in pain behavior was seen after administra-
tion of 8.4 and 28.1 mg/kg xanomeline and the effect was 
reversed by atropine, an mAChR antagonist. The reduction 
in pain behavior after VU0152100 administration was not 
significant, but a trend towards antinociception was seen, 
which was reversed by atropine. The receptor saturation 
binding study performed with [3H] N-methylscopolamine 
on spinal cord tissue from the African naked mole-rat 
resulted in saturable specific binding, but it was not pos-
sible to determine to which mAchR subtype(s). These data 
therefore suggest that mAChRs are present in the African 
naked mole-rat and that they contribute to the regulation of 
pain transmission, but that further investigations are needed 
to give more definitive answers regarding the distribution 
and function of mAChR subtypes M1 and M4 in the naked 
mole-rat.
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